Inventiva SA (NASDAQ:IVA) announced the publication in the peer-reviewed scientific journal Nature Communications of additional results from its NATIVE Phase 2b trial demonstrating the improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor.
Following lanifibranor treatment, the trial demonstrated significant improvement in patients with metabolic dysfunction-associated steatohepatitis (MASH)/ non-alcoholic steatohepatitis (NASH) with and without Type 2 Diabetes and with or without obesity of markers of cardiometabolic health.
In February, Inventiva announced it stopped enrolling new patients in the NATiV3 Phase 3 trial for lanifibranor in NASH due to a reported serious adverse reaction. This reaction involved elevated liver enzymes in a patient undergoing treatment.
Lanifibranor treatment also led to lower fasting glucose to normal levels in 71% ...